Mitralign, Inc., a developer of transcatheter tricuspid and mitral valve repair solutions, has completed subject enrollment in the SCOUT U.S. early feasibility study.
“This is the first U.S. early feasibility study to complete enrollment using a transcatheter device to treat the tricuspid valve. The SCOUT Study marks initiation of the path to evaluate catheter-based tricuspid repair for patients suffering from tricuspid regurgitation,” said Rick Geoffrion, Chief Executive Officer of Mitralign. “We are pleased to announce we have also recently received approval to expand the study and enroll an additional cohort of subjects in the United States.”
“The clinical community is excited about the potential opportunity to provide a breakthrough non-surgical option for patients with tricuspid regurgitation. We know the number of people suffering with tricuspid regurgitation is much bigger than previously reported, and we are in the nascent stages of treating this large, unaddressed population,” said Rebecca Hahn, M.D., Director of Interventional Echocardiography at NewYork-Presbyterian/Columbia University Medical Center and Principal Investigator for the SCOUT Study. “The Trialign System leaves behind a very small footprint, so we believe this device has the potential to be a front line solution for patients with functional TR.”
The Trialign System is an investigational device and is limited by Federal (or United States) Law to investigational use. The Mitralign Percutaneous Annuloplasty System (MPAS) received CE mark approval in February for the treatment of functional mitral regurgitation (FMR) and is not commercially available in the U.S.